TCRX

TScan Therapeutics, Inc. Common Stock

1.02

USD

TCRX Earnings Reports

Positive Surprise Ratio

TCRX beat 12 of 18 last estimates.

67%

Next Report

Date of Next Report

Mar 04, 2026

Estimate for Q4 25 (Revenue/ EPS)

$2.09M

-$0.24

Implied change from Q3 25 (Revenue/ EPS)

-16.81%

-14.29%

Implied change from Q4 24 (Revenue/ EPS)

+214.13%

-20.00%

TScan Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, TCRX reported earnings of -0.28 USD per share (EPS) for Q3 25, beating the estimate of -0.30 USD, resulting in a 7.04% surprise. Revenue reached 2.51 million, compared to an expected 2.02 million, with a 24.33% difference. The market reacted with a -2.46% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.24 USD, with revenue projected to reach 2.09 million USD, implying an decrease of -14.29% EPS, and decrease of -16.81% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

Regeneron Pharmaceuticals Inc

Report Date

Jan 30, 2026 For Q4 25

Estimate

$10.84

Actual

$11.44

Surprise

+5.52%

FAQ

What were TScan Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, TScan Therapeutics, Inc. Common Stock reported EPS of -$0.28, beating estimates by 7.04%, and revenue of $2.51M, 24.33% above expectations.

How did the market react to TScan Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved down -2.46%, changed from $1.22 before the earnings release to $1.19 the day after.

When is TScan Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 04, 2026.

What are the forecasts for TScan Therapeutics, Inc. Common Stock's next earnings report?

Based on 9 analysts, TScan Therapeutics, Inc. Common Stock is expected to report EPS of -$0.24 and revenue of $2.09M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.